D
espite the availability of many new immunosuppressive drugs, treatment of lupus nephritis (LN) remains a major challenge. Management of LN typically consists of an initial induction phase to achieve rapid remission, followed by a long-term maintenance phase to prevent disease relapse. Induction therapy is particularly important because patients with complete remission typically have a better prognosis, with fewer episodes of relapse, than patients who do not achieve remission (1, 2) . However, the incidence of complete remission with current induction therapy regimens, such as mycophenolate mofetil (MMF) and cyclophosphamide, remains low (3) (4) (5) (6) (7) . Therefore, more effective induction regimens for LN are needed.
We hypothesized that induction therapy comprising multiple drugs targeting different aspects of the immune response would be more effective than a single agent and, further, that lower doses of multiple drugs may maximize efficacy and minimize adverse effects (8, 9) . For decades, a multitarget approach has been the basis of antirejection therapy following solid organ transplantation (10 -12) .
Controlled clinical trials have established MMF as an option for induction treatment of LN and maintenance of renal response following induction (4, 13). Relative specificity for activated lymphocytes as well as antiproliferative and antifibrotic actions may be responsible for some of MMF's beneficial effects in LN (14) . Tacrolimus is a calcineurin inhibitor and a potent inhibitor of human T-cell proliferation. Several recent studies have confirmed that calcineurin inhibitors have a protective effect on glomerular podocytes independently of immunosuppressive effects (15, 16) . These findings may explain the underlying mechanism of tacrolimus's antiproteinuric effect, which has been observed in the treatment of glomerular diseases, especially membranous lesions (17, 18) . Previous studies have also shown that tacrolimus is effective, well tolerated, and safe for induction and maintenance therapy for LN (17, 19 -21) .
We conducted a pilot study to evaluate a multitarget LN induction regimen that combined tacrolimus, MMF, and steroids. In this study, the multitarget regimen demonstrated a higher incidence of complete remission and overall response in patients with concurrent class IV and V LN compared with intravenous
Setting and Participants
Patients age 18 to 65 years with biopsy-proven LN diagnosed within 6 months before enrollment (class III, IV, V, III+V, and IV+V LN according to International Society of Nephrology/Renal Pathology Society 2003 classification) who fulfilled the American College of Rheumatology classification criteria for systemic lupus erythematosus (SLE) were recruited from 26 renal centers across China (22) . Patients must have had proteinuria (at least 1.5 g/d) with a serum creatinine level of 3.0 mg/dL or less (≤265.2 μmol/L). Key exclusion criteria included previous treatment with MMF, cyclophosphamide, tacrolimus, or high-dose methylprednisolone; current renal replacement therapy, plasmapheresis, or intravenous gamma globulin therapy within the 12 weeks before randomization; abnormal liver function or serum glucose test results; and pathologic chronicity index greater than 3. Details of patient inclusion, exclusion, and withdrawal criteria are available in the Supplement.
Randomization and Interventions
The randomization list, stratified by center, was created by Rundo International Pharmaceutical Research & Development (Shanghai) Co. Ltd. by using computergenerated random-number sequences (SAS software, SAS Institute). Sequentially numbered, concealed envelopes containing group assignment were provided to the investigators. After eligible patients provided written informed consent, investigator opened the envelopes in sequence and patients were randomly assigned, in a 1:1 ratio, to the multitarget regimen or IVCY.
Patients in both groups received intravenous methylprednisolone pulse therapy (0.5 g/d) for 3 days, followed by oral prednisone (0.6 mg/kg per day) every morning for 4 weeks. The daily dose of prednisone was tapered by 5 mg/d every 2 weeks to 20 mg/d and then by 2.5 mg/d every 2 weeks to a maintenance dose of 10 mg/d. After methylprednisolone pulse therapy, the multitarget group received MMF (0.5 g twice daily) and tacrolimus (2 mg twice daily). For patients in the IVCY group, after completion of methylprednisolone pulse therapy, IVCY was initiated at a dose of 0.75 g/m 2 body surface area and then adjusted to a dose of 0.5 to 1.0 g/m 2 body surface area every 4 weeks for 6 doses.
Outcomes and Follow-up
The primary end point was the incidence of complete remission after 24 weeks of induction therapy, defined as a 24-hour urinary protein excretion of 0.4 g or less, the absence of active urine sediments, serum albumin level of 35 g/L or greater, and normal serum creatinine. Secondary end points included the incidence of overall response (complete remission and partial remission [≥50% reduction in proteinuria and urine protein <3.5 g/24 hours, serum albumin level ≥30 g/L, and normal or ≤25% increase in serum creatinine level from baseline]); time to overall response; incidence of complete remission and overall response in patients with different pathologic classes of LN; extent of changes in proteinuria, serum albumin, serum creatinine, estimated glomerular filtration rate, SLE Disease Activity Index (SLE-DAI), C3 and C4; and negative conversion ratio of anti-double-stranded DNA. The out-
EDITORS' NOTES Context
Current induction therapy regimens for lupus nephritis (LN) have low rates of complete remission. A drug regimen that targets different components of the immune response might be more effective and have fewer adverse effects than a single drug regimen.
Contribution
Patients with LN were randomly assigned to a multitarget regimen consisting of tacrolimus and mycophenolate mofetil or intravenous cyclophosphamide for 24 weeks. Both groups also received corticosteroid therapy.
Caution
Long-term outcomes (>6 months) were not collected.
Implications
The multitarget induction regimen yielded higher rates of complete remission compared with intravenous cyclophosphamide among patients with LN. The groups had similar adverse event rates.
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Patients were evaluated at weeks 2 and 4, and then every 4 weeks until 24 weeks. During each visit, researchers evaluated whether the patient experienced increased SLE activity or a doubling of serum creatinine. Renal biopsy specimens from baseline and repeated biopsies at week 24 were examined centrally. Two renal pathologists classified the specimens and scored the pathologic variables (that is, pathologic activity index and chronicity index) independently. A committee of physicians and pathologists discussed and adjudicated the cases in which the pathologists' assessments differed. Study drug adherence was calculated by dividing the amount of drug ingested by the amount the patient should have ingested and multiplying that value by 100%. Safety assessments included histories and physical examinations, laboratory tests, concentrations and doses of tacrolimus and MMF, and adverse events.
Statistical Analysis
This trial was designed to test the null hypothesis that multitarget therapy is not superior to standard IVCY treatment in inducing complete remission after 24 weeks of treatment. On the basis of published data, the complete remission incidence at 24 weeks in IVCY induction therapy was estimated to be 20% (4, 23, 24) . Assuming a 15% increase in the incidence of complete remission in the multitarget group and using an ␣ value of 0.05 and ␤ value of 0.2, we required a sample size of 302. To account for loss to follow-up, we planned to recruit 362 patients for this study.
The efficacy and safety analysis sets included all randomly assigned patients who received at least one dose of study medication. Categorical variables (for example, complete remission, overall response, and adverse experiences) were analyzed by using Fisher exact tests. Continuous variables (such as laboratory tests) were analyzed by using a t-test, Wilcoxon signed-rank test, or Wilcoxon rank-sum test if the data were skewed. Kaplan-Meier estimates of the cumulative probability of complete remission and overall response and median time to overall response were calculated; the betweengroup difference was compared by using the log-rank test (PROC LIFETEST). The 95% CIs of difference in cumulative probability and time to overall response were estimated by using the bootstrap method. For complete remission and overall response, the data were assumed to be missing at random, and multiple imputation was used to impute missing values for patients who did not complete the entire study regimen (25) . Sensitivity analyses were done to assess the possible effect of dropout on the results. A nonresponder analysis, prespecified as the primary analysis in the protocol, considered all patients who did not complete the study or who were missing response data as nonresponders. In addition, a post hoc complete case analysis, longitudinal data analysis, and pattern mixture model analysis were done. The frailty model was used to estimate the hazard ratio with adjustment for center (26) . Additional details on the statistical analyses are provided in Appendix 2, available at www.annals.org. Statistical analyses were performed by using SAS software, version 9.2. Plots were generated with the STS graph in Stata software, version 9.0 (StataCorp). Differences were determined to be statistically significant when the two-sided P value was less than 0.05.
Role of Funding Source
The funding source had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.
RESULTS

Patients
Between April 2009 and June 2011, 368 patients were enrolled and randomly assigned to 1 of the 2 treatment groups; about half had new-onset LN. Six patients in the IVCY group did not receive any treatment after randomization. Baseline disease and demographic characteristics are shown in Table 1 . Fifty-two patients-26 in each group-discontinued the study early ( Figure 1 ). The median (25th, 75th percentiles) duration of follow-up for these patients was 11.9 (4.6, 16.3) weeks in the multitarget group and 6.6 (2.6, 12.7) weeks in the IVCY group. One hundred fifty-five participants completed the 24-week induction treatment in each group; the multitarget group and IVCY group had 38 and 80 missing visits, respectively.
Treatments
The multitarget group received MMF and tacrolimus at an initial dosage of 1.0 g/d and 4 mg/d, respectively. Drug dosages were adjusted according to the concentration or adverse events. The mean blood concentration of study drugs was stable throughout the study (Appendix Table 1 ). The prednisone dosage was gradually tapered and was similar between the two treatment groups. In the multitarget group, 95% of patients adhered to MMF and tacrolimus; in the IVCY group, the adherence rate was 92%. Four multitarget recipients and 5 IVCY recipients did not adhere to the protocol and were withdrawn from the study.
Efficacy
Significantly more patients in the multitarget group than in the IVCY group achieved complete remission at 24 weeks (45.9% vs. 25.6%; difference, 20. Table 3 , available at www.annals .org).
The overall (complete and partial remission) response incidences at week 24 were 83.5% in the multitarget treatment group and 63.0% in the IVCY group (difference, 20.4 percentage points [CI, 10.3 to 30.6 percentage points]; P < 0.001) (Appendix Table 4 Figure 3 ). Median time to overall response was 8.9 weeks (CI, 7.7 to 9.9 weeks) in the multitarget group and 13.0 weeks (CI, 11.3 to 16.1 weeks) in the IVCY group (difference, Ϫ4.1 weeks [CI, Ϫ7.9 to Ϫ2.1 weeks]). The incidence of complete remission was higher in the multitarget group than in the IVCY group among patients with class IV LN (51.5% vs. 29 Table  5 , available at www.annals.org).
Repeat Renal Biopsy
Twenty-three patients underwent repeat renal biopsies with signed consent after treatment. Repeat renal biopsies revealed a marked reduction in the patho- Anti-dsDNA = anti-double-stranded DNA; eGFR = estimated glomerular filtration rate; LN = lupus nephritis; SLE-DAI = systemic lupus erythematosus disease activity index. This
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The incidences of upper gastrointestinal symptoms Table 2) .
DISCUSSION
Lupus nephritis, a heterogeneous and difficult-totreat disorder, presents a serious clinical challenge. Because immune dysregulation is fundamental to pathogenesis of LN, with both B and T cells involved in the development of the disease (27) , it may be necessary to target multiple aspects of the immune response using combined immunosuppressants. To our knowledge, this study is the first multicenter, randomized trial to demonstrate that a multitarget combination regimen of MMF, tacrolimus, and steroids for LN results in higher complete remission and overall response rates compared with IVCY, with similar incidences of adverse events. In addition, the multitarget group had greater recovery of complement levels and reductions in SLE-DAI score and shorter time to overall response compared with the IVCY group. Although more multitarget recipients than IVCY recipients dropped out of the study because of adverse events, the incidence of adverse events overall was similar in both groups. These findings strongly support the multitarget regimen as a superior induction regimen for LN compared with IVCY.
We searched PubMed and MEDLINE for articles published in any language between October 2008, when the results of our pilot study were reported, and This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways. Other small studies and a systematic review reported that tacrolimus is effective and safe for induction treatment of LN, and two more recent studies showed that tacrolimus had similar efficacy compared with MMF in this treatment setting (7, 17, 19, 28) . Of note, Austin and colleagues reported that patients with membranous LN who were treated with a calcineurin inhibitor tended to achieve remission more rapidly than those who were treated with IVCY (18) . Although the multitarget therapy for the current study yielded a much higher incidence of complete remission and overall response than did previous studies, the incidence of these outcomes in the IVCY group was also higher than in the study by Ginzler and colleagues (4) . On the other hand, the incidence of complete remission and overall response for the IVCY group was similar to findings reported in ALMS and several other Chinese studies (3, 21, 29) . One possible explanation for the relatively high incidence of response in the IVCY group is that Chinese patients with LN are more susceptible to immunosuppressive agents than patients from other ethnic groups (3, 30) . Notably, exploratory subanalyses of the ALMS data set could not demonstrate significant differences in treatment response between Chinese and non-Asian patients (3, 31) .
Current approaches to LN management have largely been guided by histologic findings (22, 32) . As such, pathologic data from kidney biopsies performed at baseline and at 24 weeks in our study suggest that This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.
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multitarget therapy induces not only clinical remission but also histologic remission. However, a relatively small proportion of the patients in our trial had repeat biopsies. Because patients with different pathologic classes of LN may respond to therapy differently and have different prognoses, LN class is an important consideration in selecting therapy (9) . Subgroup analyses showed that patients with class IV and V LN achieved higher rates of complete remission with multitarget therapy than with IVCY. These findings suggest that multitarget therapy may be a valuable treatment approach in patients with class IV (proliferative LN) and class V (membranous LN) lesions. Because this study was conducted in Chinese patients, further studies are required to validate whether the efficacy of the multitarget therapy can be generalized to patients with LN who are of non-Asian ethnicity. However, this limitation does not diminish the importance of the findings reported because it is common for a novel treatment regimen to be investigated in one ethnic group before the results can be replicated in a wider population. Although the timing of the induction phase and efficacy evaluations were based on previously reported trials, 6 months may be too short to differentiate between study treatments because the disease may continue to improve (3, 4, 23) . Therefore, assessment of longer-term renal survival rates would provide valuable data to support the benefits of multitarget therapy. Another limitation of the study is that patients with renal chronicity index greater than 3 were excluded, which may have excluded some patients with chronic disease that later became more severe. Finally, the study did not include an MMF monotreatment group, and thus we were cannot compare the multitarget regimen to MMF alone.
In conclusion, multitarget therapy with tacrolimus and MMF was superior to IVCY as an induction treatment of LN, as indicated by higher incidence of complete remission and overall response as well as more rapid response to treatment. Adverse event profiles were similar between the 2 treatment regimens. Therefore, the multitarget regimen should be considered as an alternative to conventional therapy for induction treatment of LN. It would be interesting to investigate this multitarget regimen for use as maintenance therapy for LN. 
Multiple Imputation for Missing Data
We assumed the data to be missing at random; the multiple imputation with fully conditional specification method was used to handle the missing data. We used the multiple imputation procedure to generate 10 imputed data sets. The initial data set to impute contained all the parameters used to judge the response (24-hour urinary protein excretion, serum albumin, serum creatinine, treatment group, and LN pathologic class). For the longitudinal laboratory data, the same variable at different time points and the different variables at the same time point were forced to be included in the imputation model.
We analyzed complete remission and overall response for all patients and in pathologic class subgroups at week 24 for each of the 10 data sets. Then we used the MIANALYZE procedure to combine the results of different imputed data sets.
Sensitivity Analyses
We performed various sensitivity analyses to evaluate the effect of the missing data and assumptions regarding them. To use all available data, a longitudinal data analysis and a pattern mixture model (34) were applied. Considering the longitudinal nature of the measurements at different visits, we performed a mixed-effect logistic model analysis that included treatment group, visit, and the interaction between the treatment group and visit as fixed effects; study center and subject were random effects. The analysis was performed by using the GLIMMIX procedure with binomial distribution, logit link, and compound symmetry covariance structure. The incidences and differences between groups were estimated by using the leastsquares method (LSMEANS statement). This longitudinal analysis approach assumed the missing data were missing at random.
The second approach was longitudinal pattern mixture model, which assumes that the missing data may not be missing at random. This model included the same effects as the longitudinal logistic regression model but included an effect for dropout (a variable that indicated an individual is dropout or not), as well as its interactions with treatment and visit. The GLIMMIX procedure and its LSMEANS statement were also used to build the pattern mixture model.
In addition, we reanalyzed the data on patients with complete response data and on all patients and considered those with missing data to be nonresponders. (Appendix Table 3 )
Frailty Model for Hazards Ratio
Because this study is a multicenter study, we performed frailty model analyses that included the center as a random effect (frailty) (26, 35, 36) . For complete remission and overall response, hazards ratios for treatment group were estimated by using the frailty model, which included treatment as an explanatory variable and center as its cluster variable. PROC PHREG was used. This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways. This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways. 
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